SCHEMBL1370980

SCHEMBL1370980

NC(COC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.57
SLC1A1 P43005 5/20 0.55
ALPI P09923 1/20 0.53
PKM P14618 1/20 0.53
PTGS1 P23219 1/20 0.53
XIAP P98170 1/20 0.53
SLC7A5 Q01650 1/20 0.53
SLC1A5 Q15758 1/20 0.53
SLC1A3 P43003 4/20 0.50
SLC15A1 P46059 1/20 0.49
SLC1A2 P43004 3/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1370981 1.00 IDO1 (0.57) IDO1SLC1A1ALPIPKMPTGS1
SCHEMBL7029223 0.84 IDO1 (0.56) IDO1SLC1A1ALPIPKMPTGS1
SCHEMBL26759630 0.83 ALDH1A1 (0.53) SLC1A1SLC1A3SLC15A1SLC1A2KMT2A
SCHEMBL4220364 0.82 LTA4H (0.51) IDO1SLC1A1SLC7A5SLC15A1KMT2A
SCHEMBL15502155 0.82 ALDH1A1 (0.47) SLC1A1SLC1A3SLC1A2KMT2AMEN1
SCHEMBL37382 0.82 ALDH1A1 (0.68) KMT2AALDH1A1MAPK1L3MBTL1SLC6A2
SCHEMBL561330 0.81 SLC1A1 (0.73) IDO1SLC1A1ALPIPKMPTGS1
SCHEMBL185608 0.81 SLC1A1 (0.73) IDO1SLC1A1ALPIPKMPTGS1
SCHEMBL2037281 0.81 SLC1A1 (0.73) IDO1SLC1A1ALPIPKMPTGS1
SCHEMBL20825448 0.80 SLC1A1 (0.63) IDO1SLC1A1ALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794663-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF Angiochem Inc. (CA) 2014-10-29 EP disclosed
US-20110288011-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF ANGIOCHEM INC. (CA) 2011-11-24 US disclosed
WO-2010063124-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF ANGIOCHEM INC. (CA) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288011-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF VIP, SLC1A5, SLC47A1 IDO1 3149/4885SLC1A1 25/4885ALPI 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.